tbuckley/cabot-search huggingface dataset:
Remodeling tumor immunosuppressive microenvironment through dual activation of immunogenic panoptosis and ferroptosis by H2S-amplified nanoformulation to enhance cancer immunotherapy
Authors: Yingli Luo, Maoyuan Linghu, Xianyu Luo, Dongdong Li, Jilong Wang, Shaojun Peng, Yinchu Ma
Journal: Acta Pharmaceutica Sinica B (2024)

The deficiency in immunogenicity and the presence of immunosuppression within the tumor microenvironment significantly hindered the efficacy of immunotherapy. Consequently, a nanoformulation containing metal sulfide of FeS and GSDMD plasmid (NPFeS/GD) had been developed to effectively augment antitumor immune responses through dual activation of immunogenic PANoptosis and ferroptosis, as well as reprogramming immunosuppressive effects via H2S amplification. The bioactive NPFeS/GD exhibited controlled release of GSDMD plasmid, H2S, and Fe2+ in response to the tumor microenvironment. Fe2+, H2S, and the expression of GSDMD protein could effectively elicit highly immunogenic PANoptosis and ferroptosis. Furthermore, releasing H2S could mitigate the overexpression of indoleamine 2,3-dioxygenase1 (IDO1) induced by immunogenic PANoptotic and ferroptotic cell death and disrupt the activity of IDO1. Consequently, NPFeS/GD effectively triggered the antitumor innate and adaptive immune responses through induction of PANoptotic and ferroptotic cell death and reshaped the tumor immunosuppressive microenvironment to enhance antitumor immunotherapy for metastasis inhibition. This study unveiled the significant potential of immunogenic PANoptosis and ferroptosis in H2S gas therapy for enhancing tumor immunotherapy, offering novel insights and ideas for the rational design of nanomedicine to enhance tumor immunogenicity while reprogramming the tumor immunosuppressive microenvironment.
PPS-TLR7/8 Agonist Nanoparticles Equip Robust Anticancer Immunity by Selectively Prolonged Activation of Dendritic Cells
Authors: Yingxi Zhang, Yicheng Li, Zhaochu Xu, Linyi Xu, Yue Wang, Ning Li, Nicholas Solek, Yongjun Wang, Bowen Li, Hongzhuo Liu
Journal: Biomaterials (2024)
Refractive change at 5 years in the Toddler Aphakia and Pseudophakia Study (TAPS)
Authors: Deborah K VanderVeen, Edward Wilson, Jenny Y Wang, M Elias I Traboulsi, Sharon F Freedman, David A Plager, Kimberly G Yen, Natalie C Weil, Allison R Loh, David Morrison, Jill S Anderson, Scott R Lambert, Erick D Bothun
Journal: Ophthalmology (2024)
A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis
Authors: Silvio Danese, Michael E Rothenberg, Jeremy J Lim, Han Ting Ding, Jacqueline M McBride, Yiling Chen, Ajit Dash, Jordan S Mar, Mary Keir, Laurent Peyrin-Biroulet, Julian Panes, Jean-Frederic Colombel, Brian Feagan, John F Valentine, Stefan Schreiber
Journal: Clinical Gastroenterology and Hepatology (2024)
Global Trend of MASH-associated Liver Cancer A Systematic Analysis from the Global Burden of Disease 2021
Authors: Pojsakorn Danpanichkul, Kanokphong Suparan, Chuthatip Kaeosri, Pimtawan Jatupornpakdee, Abdelrahman M Attia, Thanathip Suenghataiphorn, Jerapas Thongpiya, Banthoon Sukphutanan, Daniel Q Huang, Mazen Noureddin, Amit G Singal, Karn Wijarnpreecha, Ju Dong Yang
Journal: Clinical Gastroenterology and Hepatology (2024)
Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA)
Authors: Francesco Passiglia, Angela Listì, Paolo Bironzo, Alessandra Merlini, Federica Benso, Francesca Napoli, Francesca Alice Barbu, Vanessa Zambelli, Fabrizio Tabbò, Maria Lucia Reale, Claudio Sini, Elisa Roca, Paola Adriana Taveggia, Francesca Simionato, Lucio Buffoni, Laura Mazilu, Vito Barbieri, Daniele Pignataro, Antonio Araujo, Luis Paz-Ares, Enriqueta Felip, Nevena Secen, Alina Comanescu, Kleida Mati Ramizi, Anna Cecilia Bettini, Vieri Scotti, Helena Linardou, Katja Mohorcic, Giulia Meoni, Diana Giannarelli, Marco Volante, Umberto Malapelle, Stefania Vallone, Giorgio Scagliotti, Luisella Righi, Silvia Novello
Journal: Journal of Thoracic Oncology (2024)
Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn’s Disease; a prospective multicenter study
Authors: Kento Takenaka, Tadakazu Hisamatsu, Taku Kobayashi, Hironori Yamamoto, Naoki Ohmiya, Ryohei Hayashi, Katsuyoshi Matsuoka, Masayuki Saruta, Akira Andoh, Norimasa Fukata, Kenji Watanabe, Hiroyuki Imaeda, Fumihito Hirai, Takayuki Matsumoto, Akihiro Hirakawa, Tomonori Yano, Minoru Matsuura, Ryuichi Okamoto, Kazuo Ohtsuka, Mamoru Watanabe
Journal: Clinical Gastroenterology and Hepatology (2024)
Hypercoagulation after Hospital Discharge in Acute Severe Ulcerative Colitis: A Prospective Study
Authors: Benjamin J Griffiths, Michael J R Desborough, Marjolijn Duijvestein, Geert R A D'Haens, Yuhong Yuan, Robert V Bryant, Nicola Curry, Simon P L Travis, Vipul Jairath
Journal: Clinical Gastroenterology and Hepatology (2024)
LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer
Authors: Aurélie Swalduz, Camille Schiffler, Hubert Curcio, Bana Ambasager, Gabriel Le Moel, Didier Debieuvre, Jean-Marc Dot, Michael Duruisseaux, Pierre Fournel, Luc Odier, Sylvie Demolombe, Acya Bizieux-Thaminy, Annie Peytier, Roland Schott, Stéphane Hominal, Claire Tissot, Pierre Bombaron, Séverine Metzger, Mathilde Donnat, Sandra Ortiz-Cuaran, Nitzan Rosenfeld, Christodoulos Pipinikas, Pierre Saintigny, Maurice Pérol
Journal: Journal of Thoracic Oncology (2024)
Low miR-224-5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4
Authors: Yan-yan Yan, Zhuo-fen Deng, Xing-tao Wu, Yu Lu, Zhuang-yan Zhu, Qing Wen, Wei Zhang, Hai-yan Zhang, Xin-zhu Chen, Yu-song Wu, Xue-bing He, Zi-ang Ma, Jin-shuo Li, Hong Bi, Jian-ye Zhang
Journal: Drug Resistance Updates (2024)
Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy
Authors: Christian Tibor Josef Magyar, Grainne Mary O'Kane, Laia Aceituno, Zhihao Li, Arndt Vogel, Jordi Bruix, Vincenzo Mazzaferro, Gonzalo Sapisochin
Journal: Journal of Clinical Oncology (2024)

Liver transplantation (LT) has been accepted as a cornerstone of care in hepatocellular carcinoma (HCC) for almost three decades. In recent years, its role has been evolving to include patients with disease burden beyond the widely used Milan criteria. The integration of dynamic biomarkers such as alpha-fetoprotein together with downstaging approaches and tumor evolution after enlistment has allowed the selection of patients most likely to benefit, resulting in 5-year survival rates greater that 70%. With the increasing use of immune checkpoint inhibitors (ICIs) across all stages of disease, alone or in combination with locoregional therapies, there is now the potential to further expand the patient population with HCC who may benefit from LT. This brings challenges, given the global shortage of organs and the need to better understand the optimal use of ICIs before transplantation. Furthermore, the field of transplant oncology awaits additional biomarkers that can predict those likely to benefit from ICIs. More than ever, a multidisciplinary approach for liver cancer management is critical to ensure all patients are considered for LT where appropriate, and do not miss the opportunity for long-term survival.
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)
Authors: Daniel M. Geynisman, Philip H. Abbosh, Eric Ross, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari, James R. Mark, Lambros Stamatakis, Jean H. Hoffman-Censits, Rosalia Viterbo, Richard E. Greenberg, Thomas M. Churilla, Eric M. Horwitz, Mark A. Hallman, Marc C. Smaldone, Robert Uzzo, David Y.T. Chen, Alexander Kutikov, Elizabeth R. Plimack
Journal: Journal of Clinical Oncology (2024)

PURPOSE Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are associated with pathologic downstaging after NAC. We hypothesized that a combination of biomarker selection and clinical staging would identify patients for cystectomy-sparing active surveillance (AS). PATIENTS AND METHODS We conducted a single-arm, phase II, noninferiority trial to evaluate a risk-adapted approach for MIBC. Patients with cT2-T3N0M0 MIBC underwent NAC with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). Pre-NAC transurethral bladder tumor specimens were sequenced for mutations in ATM , ERCC2 , FANCC , and RB1 . Patients with ≥1 mutation and cT0 post-NAC began AS. The primary end point was metastasis-free survival (MFS) at 2 years for the entire cohort with the null hypothesis rejected if the lower bound exact one-sided 95% CI exceeds 64%. RESULTS Seventy patients were enrolled, 33 (47%) had a mutation, and 25 (36%) began per-protocol AS. With a median follow-up of 40 months, the 2-year MFS for all patients was 72.9% (lower bound exact one-sided 95% CI, 62.8). The 2-year MFS was 76.0% in the AS group (95% CI, 54.2 to 88.4) and 71.1% (95% CI, 55.5 to 82.1) in the remaining patients. In the AS group, 17 patients (68%) had some recurrence and 12 (48%) were metastasis-free with an intact bladder. The 2-year overall survival (OS) was 84.3% (95% CI, 73.4 to 91.0); OS was 88.0% (95% CI, 67.3 to 96.0) and 82.2% (95% CI, 67.6 to 90.7) in the AS and not-AS groups, respectively. CONCLUSION Patients with MIBC treated with AMVAC followed by a risk-adapted approach to local consolidation achieved a 2-year MFS rate of 73%. The primary end point was not met, but 17% of all enrolled patients and 48% of the AS group avoided cystectomy without metastatic disease.
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Authors: Van K. Morris, Erin B. Kennedy, Manik A. Amin, Olivia Aranha, Al B. Benson, Jennifer A. Dorth, David P. Horowitz, Hagen F. Kennecke, Stefano Kim, Lillian Kreppel, Niharika B. Mettu, Lakshmi Rajdev, Rachel Riechelmann, Terence T. Sio, Cathy Eng
Journal: Journal of Clinical Oncology (2024)

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgement. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard-of-care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only). PURPOSE To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. METHODS A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations. RESULTS The systematic review contained three randomized controlled trials and three nonrandomized studies of interventions that were relevant to the guideline topic and informed the recommendations. RECOMMENDATIONS Mitomycin-C (MMC) with a fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing component of chemoradiation (CRT) for anal cancer; the Expert Panel recognizes that capecitabine is often used as an orally administered alternative to FU and is currently being used in ongoing clinical trials. Cisplatin with FU is an additional chemotherapy combination that may be recommended as radiosensitizing chemotherapy. Because of the myelosuppression associated with MMC, the preferable regimen for patients with immunosuppression is cisplatin and FU. Cisplatin is not recommended for patients with renal dysfunction, significant neuropathy, or hearing loss, and there is no evidence to recommend substituting carboplatin for cisplatin. Dose and schedule options for recommended chemotherapy agents are included within the full text of the guideline. Routine induction chemotherapy before CRT and additional chemotherapy after CRT are not recommended for patients with localized anal cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
DLBclass: A Probabilistic Molecular Classifier to Guide Clinical Investigation and Practice in DLBCL
Authors: Björn Chapuy, Timothy R. Wood, Chip Stewart, Andrew J. Dunford, Kirsty Wienand, Sumbul J. Khan, Nazli Serin, Meng Wang, Eleonora Calabretta, Joji Shimono, Samantha Van Seters, Sam Wiseman, Saveliy Belkin, David Isaac Heiman, Robert A Redd, Margaret A. Shipp, Gad Getz
Journal: Blood (2024)
Nasal High Flow to Modulate Dyspnea in Orally Intubated Patients
Authors: Valentine Le Stang, Mélodie Graverot, Antoine Kimmoun, Marie-Cécile Niérat, Maxens Decavèle, Thomas Similowski, Alexandre Demoule, Martin Dres
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Rationale: High flow therapy reduces dyspnea in acute respiratory failure but the underlying mechanisms are not fully elucidated. Objectives: To compare dyspnea, airway occlusion pressure (P0.1) and inspiratory work with and without nasal high flow (NHF, FiO2 21%, temperature 31°C) in intubated patients under pressure support ventilation and during a spontaneous breathing trial (SBT). Methods: Dyspnea (numerical rating scale, NRS and Mechanical Ventilation – Respiratory Distress Observational Scale, MV-RDOS), P0.1, esophageal pressure, respiratory muscles EMG, arterial blood gas were compared in intubated patients on pressure support ventilation presenting a dyspnea-NRS > 3 during two sequences: 1) pressure support ventilation with NHF at 0 L/min followed by 30, 50 and 60 L/min (the last three were randomized) and 2) a SBT with NHF at 0 and 50 L/min (randomized). Measurements and main results: Twenty patients were included. During pressure support ventilation, as compared to dyspnea-NRS that was 5 (4 – 6) at NHF 0 L/min, dyspnea-NRS was 3 (2 – 6) and 3 (2 – 5) at NHF 30L/min and NHF 50L/min, respectively (p<0.05). However, there was no change in MV-RDOS, P0.1, esophageal pressure, respiratory muscles EMG and gas exchange. During the SBT, at NHF 50 L/min, dyspnea-NRS and P0.1 were lower than during the SBT at NHF 0 L/min (p<0.01 and p=0.04 respectively) whereas MV-RDOS, esophageal pressure, respiratory muscles EMG did not change as compared to SBT with NHF 0 L/min. Conclusions: In orally intubated patients, nasal high flow was associated with lower dyspnea and lower respiratory drive without affecting the inspiratory work.
Air Hunger Far Exceeds Dyspnea Sense of Effort During Mechanical Ventilation and a Weaning Trial
Authors: Amal Jubran, Franco Laghi, Brydon J.B. Grant, Martin J. Tobin
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

No systematic investigation into dyspnea in patients receiving prolonged ventilation (>21 days) after recovering from critical-illness has been published.
Is Disease Stability an Attainable COPD Treatment Goal?
Authors: Dave Singh, MeiLan K. Han, Surya P Bhatt, Marc Miravitlles, Chris Compton, Stefanie Kolterer, Tharishini Mohan, Suneal K. Sreedharan, Lee Tombs, David M. G. Halpin
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Chronic obstructive pulmonary disease (COPD) is a heterogenous lung condition characterized by progressive airflow obstruction. Despite advancements in diagnosis and treatment, the disease burden remains high; although clinical trials have shown improvements in outcomes such as exacerbations, quality of life, and lung function, improvement may not be attainable for many patients. For patients who do experience improvement, it is challenging to set management goals given the progressive nature of COPD. We therefore propose disease stability as an appropriate and attainable treatment goal. Other disease areas have developed definitions of no disease activity or remission, which provide relevant information for defining and achieving stability for patients with COPD. Disease stability builds on related concepts already defined in COPD such as clinical control and clinically important deterioration. Current components that could form part of a disease stability definition include exacerbations, health status (including quality of life and symptoms) and lung function. Considerations should be given to intervals over which stability is defined and assessed, appropriate thresholds, and defining a composite. Ensuring a holistic approach, objective measurements and harmonious, clear communication between patients and physicians can further support establishing disease stability. Here we propose a preliminary definition of disease stability, informed by existing research in COPD. Further research will be needed to validate the framework for use in clinical and research settings. Exploring disease stability as a goal, however, is an opportunity to develop and validate an attainable treatment target to advance the standard of care for patients with COPD.
Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians
Authors: Itziar Etxeandia-Ikobaltzeta, Carolyn J. Crandall, Jennifer Yost, Douglas K. Owens, Amir Qaseem
Journal: Annals of Internal Medicine (2024)
Strategies to Address Racial and Ethnic Disparities in Health and Health Care for Chronic Conditions
Authors: Toyin Lamina, Hamdi I. Abdi, Kathryn Behrens, Romil Parikh, Kathleen Call, Amy M. Claussen, Janette Dill, Stuart W. Grande, Laura Houghtaling, Rhonda Jones-Webb, Manka Nkimbeng, Elizabeth A. Rogers, Shahnaz Sultan, Rachel Widome, Timothy J. Wilt, Mary Butler
Journal: Annals of Internal Medicine (2024)

Racial and ethnic disparities in health and health care persist in the United States, adversely affecting outcomes in prevention and treatment of chronic conditions among adults.
Successful hematopoietic cell transplantation utilizing myeloablative reduced-toxicity conditioning in Chediak-Higashi syndrome
Authors: Alan Bidgoli, Binni Kunvarjee, Andromachi Scaradavou, Richard J O'Reilly, Jaap Jan Boelens, Susan E Prockop, Joseph H Oved
Journal: Journal of Allergy and Clinical Immunology (2024)
Quantification of Epigenetic Aging in Public Health
Authors: Cynthia D.J. Kusters, Steve Horvath
Journal: Annual Review of Public Health (2024)

Estimators of biological age hold promise for use in preventive medicine, for early detection of chronic conditions, and for monitoring the effectiveness of interventions aimed at improving population health. Among the promising biomarkers in this field are DNA methylation–based biomarkers, commonly referred to as epigenetic clocks. This review provides a survey of these clocks, with an emphasis on second-generation clocks that predict human morbidity and mortality. It explores the validity of epigenetic clocks when considering factors such as race, sex differences, lifestyle, and environmental influences. Furthermore, the review addresses the current challenges and limitations in this research area.
Human papillomavirus associated vulval intraepithelial neoplasias: screening for cervical dysplasia in this cohort
Authors: Jenny G Chung, Caroline L English, Kirsten Lafferty, Joanna Burgess, Jacqueline McDermott, Sapna Harish, Charlotte E Cohen, Lucinda C Fuller, John Butler, Elaine L Palmer, Helen Staley, Randa Akel
Journal: Journal of the American Academy of Dermatology (2024)
X-ray-Activated Nanoscintillators Integrated with Tumor-Associated Neutrophils Polarization for Improved Radiotherapy in Metastatic Colorectal Cancer
Authors: Hui Li, Junyi Zeng, Qing You, Miaomiao Zhang, Yuanchao Shi, Xiaodong Yang, Wenxing Gu, Yajie Liu, Ning Hu, Yu Wang, Xiaoyuan Chen, Jing Mu
Journal: Biomaterials (2024)
Understanding immune system dysfunction and its context in mood disorders: psychoneuroimmunoendocrinology and clinical interventions
Authors: Miguel A Ortega, Oscar Fraile-Martinez, Cielo García-Montero, Raul Diaz-Pedrero, Laura Lopez-Gonzalez, Jorge Monserrat, Silvestra Barrena-Blázquez, Miguel Angel Alvarez-Mon, Guillermo Lahera, Melchor Alvarez-Mon
Journal: Military Medical Research (2024)
Endogenous retroelement activation is implicated in <scp>IFN</scp>‐α production and anti‐<scp>CCP</scp> autoantibody generation in early Rheumatoid Arthritis
Authors: Faye AH Cooles, Gemma V Pedrola, Najib Naamane, Arthur G Pratt, Ben Barron‐Millar, Amy E Anderson, Catharien MU Hilkens, John Casement, Vincent Bondet, Darragh Duffy, Fan Zhang, Ruchi Shukla, John D Isaacs
Journal: Arthritis & Rheumatology (2024)

Objectives Endogenous retroelements (EREs) stimulate type 1 interferon (IFN‐I) production but have not been explored as potential interferonogenic triggers in Rheumatoid Arthritis (RA). We investigated ERE expression in early RA (eRA), a period where IFN‐I is increased. Methods ERE expression (LTR5, LINE1, SINE) in disease modifying treatment naïve eRA whole blood and bulk synovial tissue was examined by RT‐PCR and Nanostring alongside IFN‐α activity. Circulating lymphocyte subsets, including B cell subsets, from eRA patients and early psoriatic arthritis (ePsA), were flow cytometrically sorted and similarly examined. Existing established RA and osteoarthritis (OA) synovial single‐cell sequencing data was re‐interrogated to identify repeat elements, and associations explored. Results There was significant co‐expression of all ERE classes and IFNA in eRA synovial tissue (n=22, p&lt;0.0001) and significant positive associations between whole blood LINE1 expression (n=56) and circulating IFN‐α protein (p=0.018) and anti‐CCP titres (p&lt;0.0001). ERE expression was highest in circulating eRA B‐cells, particularly naïve B‐cells compared with ePsA, with possible ERE regulation by SAMDH1 implicated and associations with IFNA again observed. Finally, in established RA synovium, LTRs, particularly ERVK, were most increased in RA compared with OA where, for all synovial subsets (monocytes, B‐cells, T‐cells and fibroblasts), ERE expression associated with increased IFN‐I signalling (p&lt;0.001). Conclusions Peripheral blood and synovial ERE expression is examined for the first time in eRA highlighting both a potential causal relationship between ERE and IFN‐I production and an intriguing association with anti‐CCP autoantibodies. This suggests EREs may contribute to RA pathophysiology with implications for future novel therapeutic strategies.